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Background: Our study aimed to assess the prognostic value of poorly differentiated clusters (PDCs) in invasive
breast cancer.
Methods: A total of 146 cases of operable invasive ductal carcinoma that was not otherwise specified (IDC-NOS), from
2002 to 2009, were pathologically reviewed. Cancer clusters with five or more cancer cells and lacking gland-like
structures were counted from a field containing maximum clusters in H & E slides under a × 20 objective lens
(0.950 mm2 field of vision).
Results: Tumors with <5, 5 to 9, and ≥10 clusters were graded as G1, G2, and G3, respectively (n =41, 60, and 45
tumors, respectively). An interobserver test showed good reproducibility, with a Cohen’s kappa coefficient of 0.739.
The PDC grade was significantly associated with N stage (P <0.001), lymphovascular invasion (P =0.007), tumor budding
grade (P <0.001), relapse rate (P <0.001), and death rate (P <0.001). Survival analyses revealed that the PDC grade was a
significant prognostic factor for disease-free survival (hazard ratio 3.811; P <0.001) and overall survival (hazard ratio
3.730; P =0.001), independent of T stage, N stage, or tumor budding grade.
Conclusions: The PDC grade is an independent prognostic factor of IDC-NOS. Considering the simplicity and
availability of this method relative to conventional clinical pathology, PDCs may serve as a novel prognostic histological
characteristic in IDC-NOS.
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In general, tumor size, nuclear grade, mitotic activity,
lymphatic and vascular invasion, and lymph node in-
volvement are common clinical pathological features of
breast cancer that can be detected by routine light mi-
croscopy. These parameters associated with the grading
and staging of breast cancer are helpful in cancer diag-
nosis and prognostic assessment [1-3] However, deter-
mination of these factors cannot always accurately
predict the biological characteristics of a tumor and the
clinical outcome [4]. For example, a survival difference
was observed clinically in patients with the same stage
who had received similar clinical treatment [5], and
more than 30% of patients with early-stage breast can-
cer have recurrent disease after effective therapy [6].
Variation in survival difference and clinical outcome* Correspondence: wangyili@mail.xjtu.edu.cn
1Center for Cancer Research, Department of Pathology, the First Affiliated
Hospital of Xi’an Jiaotong University, 710061 Xi’an, China
Full list of author information is available at the end of the article
© 2014 Sun et al.; licensee BioMed Central Ltd
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.partly suggests that standardized pathological factors
do not perfectly reflect tumor aggressiveness and risk
of recurrence and may even provide conflicting infor-
mation about a patient’s prognosis [7]. The manage-
ment of patients with breast cancer could benefit from
the use of additional hallmarks as a supplement to con-
ventional assessment.
Tumor budding is a pathological morphologic candi-
date index that has been applied to evaluate the progno-
sis of colorectal cancer [8,9], breast cancer [10], and
other cancers [11-13]. Tumor budding was defined as an
isolated single cancer cell or a microscopic cluster with
fewer than five cancer cells at the invasive frontal region
of the tumor. High intensity tumor budding reflects ma-
lignant progression and is a promising prognostic factor
for low survival rate. Tumor budding is considered to be
related to the biological processes of cancer invasion and
metastasis and was also postulated as the histological
representation of epithelial mesenchymal transition [14];. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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colorectal cancer because of its significant prognostic
value [15]. However, the use of tumor budding as a
prognostic factor has limitations: budding can be
observed only in the actively invasive frontal region;
identifying tumor budding is difficult for single cancer
cells or fairly small cell clusters in routine sections [16].
Poorly differentiated clusters (PDCs), a novel histopath-
ologic indicator, provide additional tumor bioinformation
in addition to tumor budding. These are cancer clusters
composed of five or more cancer cells and lacking gland-
like structures. The number of PDCs is highly relevant to
survival and the incidence of nodal involvement in inva-
sive colorectal cancer. A grading system based on PDCs
successfully stratifies colorectal cancer cases by survival
outcome and is believed to be useful in determining thera-
peutic strategies [17,18]. Compared with tumor budding,
counting larger clusters (≥5 cancer cells) in the whole
tumor tissue stained with H & E is a sufficiently easy
process [18]. So far, the description and prognostic value
of the PDC grading of breast cancer has not been ex-
plored. Accordingly, we evaluated the prognostic value of
PDC grading in 146 patients with invasive ductal carcin-
oma, that was not otherwise specified (IDC-NOS), which
is the most common histological type of invasive breast
cancer, and determined the relationship between PDC
grading and other known prognostic parameters.
Methods
Case selection and clinicopathological review
Our study was approved by the Ethics and Research
Committee of Shaanxi Provincial People’s Hospital. We
retrieved patient information from the patient medical
records room of Shaanxi Provincial People’s Hospital.
We reviewed all hospital records, such as inpatient
records, operative records, and outpatient clinic records.
To avoid statistical deviation from different results for
different tumor tissue types, we selected only IDC-NOS
as the targeted object. Patients were excluded from the
study if: (1) they presented with bone or distant spread
at the time of primary cancer resections; (2) they
received preoperative therapy; (3) H & E stained slides
were unavailable for review. The survey included 146
female patients with IDC-NOS who underwent curative
resections from January 2002 to December 2009. A total
of 118 patients (80.8%) received systemic adjuvant
therapies. Follow-up data were collected until death or
August 2012, with a median follow-up period of
46 months (range, 4 to 112 months). A total of 44
(30.1%) cases showed relapse, and 31 patients (21.2%)
died of tumor progression. Overall survival was defined as
the interval between the date of operation and death from
any cause. Disease-free survival was calculated from the
date of the first surgery to the date of the local or systemicrelapse or death resulting from any cause, whichever
occurred first.
Clinicopathological data were obtained from recruiting
records or by reviewing the archival H & E slides. The
median age of the patients was 52 years (27 to 84). The
histological grading was G1 in 7 cases (4.8%), G2 in 102
cases (69.9%), and G3 in 37 cases (25.3%), on the basis
of the Bloom-Richardson system and the modification
proposed by Elston and Ellis. According to the criteria of
the TNM (tumor, node, metastases) system of the
American Joint Committee on Cancer, the staging of
tumor size was T1 in 24 cases (16.4%), T2 in 105 cases
(71.9%), and T3 in 17 cases (11.6%). The presence of
lymphovascular invasion within the primary tumor was
identified in 35 cases (24.0%). The staging of node status
was N0 in 70 cases (47.9%), N1 in 44 cases (30.1%) with
one to three positive lymph node involvement and N2
or 3 in 32 cases (22.0%) with four or more positive. At
the time of primary diagnosis, no patients presented with
distant metastasis. The expression statuses of estrogen
receptor, progesterone receptor, and HER-2, as deter-
mined by immunohistochemical analysis were collected
by reviewing pathological reports. Cases were deemed
positive for expression of estrogen receptor or progester-
one receptor when at least 10% of the tumor cells had
stained nuclei. Specimens with strong complete mem-
branous staining in >30% of tumor cells were deemed
positive for HER-2 overexpression. There were 57 cases
(39.0%) with triple negative status.
Definition and assessment of poorly differentiated
clusters
Cancer clusters composed of five or more cancer cells
and lacking gland-like structures were defined as PDCs.
Using an Olympus microscope (BX-51), the entire tumor,
including its advancing edge, was first scanned at a lower
power magnification, to identify the five densest PDC
areas. Subsequently, the clusters were counted under the
microscopic field of a × 20 objective lens (field size
0.95 mm2), and the highest count of five areas per case
was used as the number of PDCs. Tumors with fewer than
five, five to nine, and ten or more clusters were graded as
G1, G2, and G3, respectively [18]. Interobserver agree-
ment was achieved for two independent observers (YS
and KW). For both observers, this study was the first time
they assessed PDCs. Discordances between the observers
were resolved by a simultaneous review using a multihead
microscope.
Definition and assessment of tumor budding
Tumor budding was determined as a single cancer cell
or as cancer clusters with fewer than five cancer cells at
the invasive front. To determine the degree of tumor
budding, like the counting method of PDCs, the clusters
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where budding was most intensively distributed. Tumors
with fewer than five, five to nine, and at least ten bud-
ding foci were classified as G1, G2, and G3, respectively
[18].
Statistical analysis
Data were analyzed using the statistical package SPSS.
Intra-observer variability was analyzed using Cohen’s
kappa coefficient. Correlation between PDC grade and
other clinicopathological variables were determined by
the chi-square test or Fisher’s exact test. The Kaplan-
Meier method and log-rank test were used in the ana-
lysis and comparison of survival curves. Univariate and
multivariate survival analyses were carried out using
Cox proportional hazards models. All analyses were
two-sided, and a P value of less than 0.05 was consid-
ered statistically significant.
Results
Correlation between poorly differentiated clusters and
other clinical pathological parameters
Both PDC grade and tumor budding were histological
findings in terms of loss of gland formation (Figure 1).
Poorly differentiated clusters often appear within a tumor
or at the advancing edge (Figure 1A,B,C). According to
the number of PDCs, 41, 60, and 45 tumors were classi-
fied as G1, G2, and G3, respectively. The interobserverFigure 1 Histologic findings of poorly differentiated cluster and tumo
show gland-like structures and are composed of up to five cancer cells, were
Single cancer cells or clusters of fewer than five cancer cells were defined as t
Both PDC grade and tumor budding are determined from histological findingtest showed good reproducibility, with a Cohen’s
kappa coefficient of 0.739 (Table 1). The PDC grade
was significantly associated with N stage (P <0.001),
lymphovascular invasion (P =0.007), tumor budding grade
(P <0.001), HER-2 overexpression (P =0.003), risk of
relapse (P <0.001), and death (P <0.001) (Table 2). Other
variables, such as age, histological grade, T stage, estrogen
receptor or progesterone receptor expression, and triple
negative status, were not significantly associated with the
level of PDCs.Prognostic significance of poorly differentiated clusters
The Kaplan-Meier curves show that the disease-free sur-
vival rates were 90.2%, 81.7%, and 35.6% for PDC grades
G1, G2, and G3, respectively. Similarly, the PDC grade
correlated with the overall survival rate. The overall sur-
vival rates were 92.7%, 85.0%, and 55.6% for PDC grades
G1, G2, and G3, respectively. Patients with PDC G3 had
significantly worse disease-free survival and overall sur-
vival rates than those with G1 (P <0.001). The disease-
free survival rate was 90.5% for G1 tumor budding,
60.0% for G2, and 42.9% for G3, whereas the overall sur-
vival rate was 92.1%, 69.1%, and 64.3% for G1, G2, and
G3 tumor budding, respectively. Compared with patients
with G1, patients with G2 and G3 tumor budding had
significantly worse disease-free survival and overall sur-
vival rates (P <0.05) (Figure 2).r budding of IDC-NOS. Cancer nests in the stroma, which do not
defined as PDCs (indicated by yellow arrows. (A) 20×; (B) 40×; (C) 100×).
umor budding (indicated by black arrows. (D) 20×; (E) 40×; (F) 100×).
s (E,F).
Table 1 Results for the repeated observation of poorly
differentiated clusters
Second review First review
G1 G2 G3 Total
G1 34 1 0 35
G2 8 48 4 60
G3 0 12 39 51
Total 42 61 43 146
Cohen’s kappa coefficient =0.739.
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age, T stage, N stage, lymphovascular invasion, HER-2
overexpression, and tumor budding grade were signifi-
cantly associated with disease-free survival and overall
survival (Tables 3 and 4). In multivariate Cox regres-
sion analysis, PDC grade (hazard ratio 3.811, P <0.001;
hazard ratio 3.730, P =0.001), T stage (hazard ratio
3.135, P <0.001; hazard ratio 4.064, P =0.001), and N
stage (hazard ratio 2.922, P =0.012; hazard ratio 3.482,
P =0.023) were identified as the independent prognos-
tic factor for disease-free survival and overall survival,
respectively (Tables 3 and 4). Tumor budding grade (haz-
ard ratio 1.808, P =0.009) was an independent prognostic
factor only for disease-free survival (Table 3).
Discussion
Pathologists are expected to provide complete informa-
tion on histological features, such as tumor description,
orientation, and analysis of surgical margins [19]. In clin-
ical practice, Elston’s modified Bloom and Richardson
method is a widely accepted tumor histological grading
system with good prognostic correlation. Histological
grade forms part of the multifactorial Nottingham prog-
nostic index, together with tumor size and lymph node
stage. The Nottingham prognostic index is used to de-
liver appropriate therapy to individual patients [20,21].
However, in practice, the grading system is not always opti-
mal, for two reasons. Disparity and diagnostic variability
between observers exists in routine pathological observa-
tion and diagnosis based on subjective opinion [19,22]. Ob-
jectively, breast cancer is characterized by generous
morphologic heterogeneity [23]. There is considerable vari-
ability in microscopic examination of histological growth
pattern and cellular differentiation. Therefore, identifica-
tion of less common histological patterns can provide clin-
ically useful data [24]. For instance, budded tumor cells at
the margin were regarded as a poorly differentiated com-
ponent, which could illustrate aggressive cancer behavior
and adverse prognosis [25,26]. Grading and typing in
breast cancer constitutes the major content of a patho-
logical report. However, the minor but key poorly differen-
tiated elements may determine clinical outcome [10]. As a
necessary complement, novel morphologic parameters thatcan be determined with simplicity, objectivity, and repro-
ducibility are required to display tumor biological features.
To date, tumor budding, as a candidate index of tumor cell
invasive potential, denotes the tumor feature in the mar-
ginal area instead of the entire tissue. Cytokeratin immu-
nohistochemical staining is required to diagnose tumor
budding accurately because identifying single cancer cells
and fairly small cell clusters in routine sections is difficult.
However, the required staining is considered a minor
inconvenience [16]. The introduction of a new histopatho-
logical parameter, that is, PDCs, in 2008 (tumor cells ≥5)
might compensate for these disadvantages [17]. In 2012,
Ueno et al. also confirmed that PDCs, which are represen-
tative of potential tumor biological aggressiveness, can be
used as robust prognostic markers [18]. The PDC-based
grading system is expected to be less subjective and more
informative for prognostic prediction, compared with con-
ventional tumor grading systems [27], TNM staging in
colorectal cancer [18,28]. Identification and counting of
PDCs in routine pathologic diagnosis is more simple and
accurate than identifying tumor budding via immunohisto-
chemical techniques [18].
In this study, we investigated the prognostic value of
PDCs in IDC-NOS. The three main findings of this study
are as follows. First, PDCs were confirmed as a signifi-
cant prognostic factor independent of classical or re-
cent pathological morphologic variables, such as tumor
size, node status, and tumor budding. Second, a high
PDC grade, representing high invasive potential, was
associated with lymph node involvement, lymphovascu-
lar invasion, high tumor budding grade, and poor clin-
ical outcome. Third, a good interobserver agreement
was found in counting PDCs.
As poorly differentiated components, both PDCs and
tumor budding are the result of histological findings in
terms of loss of gland formation. Poorly differentiated
clusters often appear within a tumor and at the advan-
cing edge, whereas tumor budding is observed in the
actively invasive frontal region [18]. In this study, a
higher PDC grade (G2, G3) was significantly associated
with tumor aggressive and invasive indexes, such as N
stage, lymphovascular invasion, and higher tumor budding
grade. A feasible explanation is that PDCs, like tumor
budding, present the epithelial mesenchymal transition of
neoplastic cells with acquired properties of tumor stem
cells [26,28-30]. The PDC grade is correlated with the
prognosis of IDC-NOS patients, since a higher PDC grade
(G2, G3) correlated with a high relapse and death rate,
and PDC G3 exhibited shorter disease-free survival and
overall survival times. A high PDC grade is a valuable
morphologic parameter, indicating tumor invasive behav-
ior and poor prognosis.
In our results, the PDC grade was not associated with
estrogen receptor or progesterone receptor expression
Table 2 Correlation between poorly differentiated clusters and other clinicopathological characteristics
Variable Poorly differentiated clusters P
G1 (%) G2 (%) G3 (%)
Age
40 or younger 3 (7.3%) 11 (18.3%) 11 (24.4%) 0.103
>40 38 (92.7%) 49 (81.7%) 34 (75.6%)
T stage
T1 8 (19.5%) 10 (16.7%) 6 (13.3%) 0.779
T2 30 (73.2%) 43 (71.7%) 32 (71.1%)
T3 3 (7.3%) 7 (11.6%) 7 (15.6%)
N stage
N0 30 (73.2%) 29 (78.3%) 11 (24.4%) <0.001*
N1 8 (19.5%) 20 (33.3%) 16 (35.6%)
N2 or 3 3 (7.3%) 11 (18.3%) 18 (40.0%)
Grade
G1 3 (7.3%) 4 (6.7%) 0 (0.0%) 0.134
G2 25 (61.0%) 42 (70.0%) 35 (77.8%)
G3 13 (31.7%) 14 (23.3%) 10 (22.2%)
Lymphovascular invasion
Negative 36 (87.8%) 48 (80.0%) 27 (60.0%) 0.007*
Positive 5 (12.2%) 12 (20.0%) 18 (40.0%)
Estrogen receptor/progesterone receptor expression
Negative 20 (48.8%) 24 (40.0%) 19 (42.2%) 0.674
Positive 21 (51.2%) 36 (60.0%) 26 (57.8%)
HER-2 overexpression
Negative 38 (92.7%) 51 (85.0%) 29 (64.4%) 0.003*
Positive 3 (7.3%) 9 (15.0%) 16 (35.6%)
Triple negative status
No 23 (56.1%) 36 (60.0%) 30 (66.7%) 0.593
Yes 18 (43.9%) 24 (40.0%) 15 (33.3%)
Tumor budding
G1 27 (65.9%) 27 (45.0%) 9 (20.0%) <0.001*
G2 11 (26.8%) 24 (40.0%) 20 (44.4%)
G3 3 (7.3%) 9 (15.0%) 16 (35.6%)
Relapse
No 37 (90.2%) 49 (81.7%) 16 (35.6%) <0.001*
Yes 4 (9.8%) 11 (18.3%) 29 (64.4%)
Death
No 38 (92.7%) 51 (85.0%) 25 (55.6%) <0.001*
Yes 3 (7.3%) 9 (15.0%) 20 (44.4%)
Total 146 41 60 45
*P <0.05.
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overexpression. However, the mechanism underlying PDC
grade and HER-2 overexpression is unclear. Considering
that fewer than 30 patients with HER-2 overexpressionwere studied and different results exist between univariate
and multivariate survival analyses on disease-free survival
and overall survival, we presumed that an accidental error
had occurred in the study. A large-scale sample is required
Figure 2 Kaplan-Meier curves of disease-free survival and overall survival in IDC-NOS as a function of grade of poorly differentiated
clusters and tumor budding. Disease-free survival and overall survival differences were significant among the different PDC grade (A,B) and
tumor budding (C,D) cohorts. (PDC, tumor budding: G3, G2 versus G1; log-rank test).
Table 3 Disease-free survival analysis by the Cox proportional hazards regression model in 146 cases of IDC-NOS
Variable Univariate Multivariate
Hazard ratio 95% confidence interval P Hazard ratio 95% confidence interval P
Age 40 or younger/>40 0.501 0.257 to 0.975 0.042* 0.826 0.414 to 1.648 0.587
T stage: T1/T2/T3 2.554 1.451 to 4.497 0.001* 3.135 1.672 to 5.879 <0.001*
N stage: N0/N1/N2 or 3 2.795 1.921 to 4.064 <0.001* 2.922 1.266 to 6.744 0.012*
Grade: G1/G2/G3 1.455 0.829 to 2.554 0.191 Not assessed
Lymphovascular invasion:
negative/positive
3.809 2.095 to 6.925 <0.001* 0.593 0.183 to 2.155 0.427
Estrogen receptor or progesterone
receptor: negative/positive
1.009 0.555 to 1.834 0.978 Not assessed
HER-2: negative/positive 2.064 1.031 to 4.133 0.041 0.820 0.383 to 1.758 0.610
Triple negative status: no/yes 1.365 0.731 to 2.551 0.329 Not assessed
Poorly differentiated cluster grade:
G1/ G2/ G3
5.086 2.998 to 8.628 <0.001* 3.811 1.992 to 7.289 <0.001*
Tumor budding: G1/G2/G3 2.554 1.721 to 3.792 <0.001* 1.808 1.159 to 2.820 0.009*
*P <0.05.
Sun et al. World Journal of Surgical Oncology 2014, 12:310 Page 6 of 8
http://www.wjso.com/content/12/1/310
Table 4 Overall survival analysis by the Cox proportional hazards regression model in 146 cases of IDC-NOS
Variable Univariate Multivariate
Hazard ratio 95% confidence interval P Hazard ratio 95% confidence interval P
Age 40 or younger/>40 0.410 0.193 to 0.869 0.020* 0.622 0.279 to 1.388 0.246
T stage: T1/T2/T3 2.956 1.513 to 5.775 0.002* 4.064 1.839 to 8.982 0.001*
N stage: N0/N1/N2 or 3 2.890 1.848 to 4.519 <0.001* 3.482 1.185 to 10.234 0.023*
Lymphovascular invasion:
negative/positive
3.841 1.909 to 7.729 <0.001* 0.516 0.106 to 2.507 0.412
Grade: G1/G2/G3 1.698 0.880 to 3.276 0.114 Not assessed
Estrogen receptor or progesterone
receptor: negative/positive
0.922 0.460 to 1.849 0.819 Not assessed
HER-2: negative/positive 2.577 1.172 to 5.668 0.019* 0.874 0.357 to 2.136 0.767
Triple negative status: no/yes 1.393 0.670 to 2.895 0.375 Not assessed
Poorly differentiate cluster grade: G1/G2/G3 4.987 2.681 to 9.276 <0.001* 3.730 1.718 to 8.101 0.001*
Tumor budding: G1/G2/G3 2.285 1.442 to 3.623 <0.001* 1.517 0.597 to 2.564 0.120
*P <0.05.
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overexpression.
In this study, PDCs and tumor budding were counted
simultaneously, and their prognostic value was assessed; it
was found that they shared common stratified standards,
according to the findings of Ueno et al. [18]. Ueno et al.
had confirmed that PDC grading is more powerful in
assessing prognostic outcome than tumor budding in
colorectal cancer [17,18]. In this study, a similar result was
found; that PDCs are an independent prognostic factor for
both relapse and death of IDC-NOS patients, while tumor
budding is an independent prognostic factor for relapse
but not death. Indeed, multivariate Cox regression analysis
of tumor budding in this study slightly disagreed with that
of a previous study [10]. We believe that the difference
between our results and those of the previous report was
caused by a disparity in cut-off value: the cut-off value was
five and ten, respectively, at three grades, instead of seven
at two grades, as with the study of Liang et al. [10]. The
change of the stratified standard led to a minimal devi-
ation in the result. Nevertheless, Kaplan-Meier curves
revealed that patients with G2 or G3 tumor budding had
significantly worse overall survival compared with those
with G1. It still strongly indicated high-level tumor
budding is highly correlated with the poor prognosis in
IDC-NOS.
More importantly, a Cohen’s kappa coefficient of 0.739
indicated a good agreement of PDC grade between two
pathologists. The interobserver test in this study, as
found in previous studies on colorectal cancer, demon-
strates that PDC grade is a reliable and reproducible
method with more objectivity for patients with IDC-
NOS. With regard to the simplicity of PDC assessment
based only on routine H & E section observation and
PDC counting within the whole tumor tissue, PDCs can
provide more morphological and prognostic informationthan conventional histology grade and tumor budding,
with no need for additional techniques or costs.
The findings in this study disclosed the clinical signifi-
cance of PDCs in IDC-NOS. A high PDC grading
reflected aggressive behavior and adverse prognosis of the
tumor. This new histological parameter could be used to
complement traditional histopathological prognostic fac-
tors in breast carcinoma. However, the PDC molecular
features remain unclear. Further exploration is necessary
to elucidate the biological significance of PDCs.Conclusions
Our results confirmed that PDCs are a reproducible, sig-
nificant, and independent prognostic factor in IDC-NOS.
The fact that a simple cell-based parameter using conven-
tional microscopy can possess such a high predictive
power is remarkable. Poorly differentiated clusters can be
viewed as morphologic candidate indexes in breast cancer.
This study is only a preliminary investigation. Further
work, such as validating prognostic value in larger sam-
ples, elucidating the underlying mechanism of PDCs, and
testing PDCs in clinical practice, is warranted.Abbreviations
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